Ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE) is a hepatoprotectant in inhibiting apoptosis, inflammation, and hyperlipidemia in mouse models of nonalcoholic steatohepatitis (NASH). We studied the ability of UDCA-LPE to inhibit palmitate (Pal)-induced apoptosis in primary hepatocytes and delineate cytoprotective mechanisms. We showed that lipoprotection by UDCA-LPE was mediated by cAMP and was associated with increases in triglycerides (TGs) and phospholipids (PLs). An inhibitor of cAMP-effector protein kinase A partially reversed the protective effects of UDCA-LPE. Lipidomic analyses of fatty acids and PL composition revealed a shift of lipid metabolism from saturated Pal to monounsaturated and polyunsaturated fatty acids, mainly, oleate, docosapentaenoate, and docosahexaenoate. The latter two v-3 fatty acids were particularly found in phosphatidylcholine and phosphatidylserine pools. The catalysis of Pal by stearoylCoA desaturase-1 (SCD-1) is a known mechanism for the channeling of Pal away from apoptosis. SCD-1 protein was upregulated during UDCA-LPE lipoprotection. SCD-1 knockdown of Pal-treated cells showed further increased apoptosis, and the extent of UDCA-LPE protection was reduced. Thus, the major mechanism of UDCA-LPE lipoprotection involved a metabolic shift from toxic saturated toward cytoprotective unsaturated fatty acids in part via SCD-1. UDCA-LPE may thus be a therapeutic agent for treatment of NASH by altering distinct pools of fatty acids for storage into TGs and PLs, and the latter may protect lipotoxicity at the membrane levels.
Introduction
Nonalcoholic steatohepatitis (NASH) is the most common form of chronic liver disease and is associated with metabolic syndrome and obesity (Diehl, 1999) . NASH is defined as lipid accumulation with cellular damage, inflammation, and different degrees of fibrosis, and it is considered a serious condition as 25% of NASH patients can progress to cirrhosis, portal hypertension, and a high risk of hepatocellular carcinoma. Numerous advances in understanding its pathogenesis have been made, thus providing a rationale for translation into clinical trials. Besides dietary modification and bariatric surgery, pharmacological interventions have been tested, including insulin sensitizers, peroxisome proliferatoractivated nuclear receptor-g agonists, tumor necrosis factor-a antagonists, lipid-lowering agents, as well as antioxidants and hepatoprotectants (Satapathy and Sanyal, 2010) . Clinical trials using insulin sensitizers, such as metformin and glitazones, have revealed ineffectiveness or only partial efficacy (Ratziu et al., 2010) . Histologic improvement of disease, at least in some patients, is observed treatment with vitamin E (Satapathy and Sanyal, 2010) and ursodeoxycholic acid (UDCA) (Ratziu et al., 2011) . High-dose UDCA (28-35 mg/kg daily) has been shown to improve aminotransferase levels, serum fibrosis markers, and selected metabolic parameters (Ratziu et al., 2011) .
UDCA is known to be a hepatoprotectant (Rodrigues et al., 1998) , anti-inflammatory (Zhang et al., 2010) , and antifibrotic agent (Zhang et al., 2010) , and it is approved for the treatment of cholestatic liver disease (Tsochatzis et al., 2009) . UDCA is efficiently taken up by bile acid transport proteins (Maeda et al., 2006) , and the coupling of UDCA at C 24 with drugs such as, 5-aminosalicylic acid (Goto et al., 2001 ) and cisplatin (Briz et al., 2002) renders efficient uptake by these transporters (Balakrishnan et al., 2006) . Moreover, the C 23 homolog of UDCA, which lacks one methylene group in its side chain, socalled norUDCA, has been shown to be a better hepatoprotectant than UDCA in the treatment of experimental sclerosing cholangitis (Fickert et al., 2006) and NASH (Beraza et al., 2011) . We rationalized that the efficacy of UDCA could be improved by coupling UDCA with a phospholipid because phospholipids are known to increase hepatocyte membrane integrity (Li et al., 2006) . We performed a coupling at C 24 of UDCA with lysophosphatidylethanolamine (LPE; 18:1n-9-lysophosphatidylethanolamine) to generate UDCA lysophosphatidylethanolamide (UDCA-LPE), the chemical structure of which is shown in Fig. 1A (Chamulitrat et al., 2009 ). UDCA-LPE was shown to be cytoprotective as an intact compound. The superiority of UDCA-LPE to UDCA has been demonstrated in terms of inhibition of tumor necrosis factor-ainduced apoptosis and protection against acute liver injury (Chamulitrat et al., 2009; Pathil et al., 2011) . Furthermore, we have shown that UDCA-LPE administration to mice fed with a high-fat diet could lower systemic and hepatic hyperlipidemia concomitant with significant inhibition of hepatocyte apoptosis and inflammation .
The hallmark of NASH includes increases in hepatocellular saturated fatty acids and subsequent lipoapoptosis. In the present study, we demonstrated that UDCA-LPE could inhibit apoptosis induced by palmitate (Pal) in mouse hepatocytes. We further investigated whether the mechanisms of lipoprotection could be mediated by cAMP (Kwon et al., 2004) and by pathways associated with the accumulation of triglycerides (TGs) (Listenberger et al., 2003) and phospholipids (PLs) (Collins et al., 2010) . By using inhibitors and performing knockdown experiments, we showed the latter to be the major mechanism involving the action of stearoyl-CoA desaturase-1 (SCD-1), an enzyme that converts saturated fatty acids (SFAs) to monounsaturated fatty acids (MUFAs) . Lipidomic data revealed that UDCA-LPE was able to induce changes in fatty acid composition in lowering cytotoxic SFA and Pal while increasing MUFA and polyunsaturated fatty acids (PUFAs), including docosapentaenoate (DPA) and docosahexaenoate (DHA). Thus, the major mechanism for UDCA-LPE lipoprotection in vitro appeared to involve alterations of fatty acid composition.
Materials and Methods
Reagents. The synthesis of UDCA-LPE was reported previously (Chamulitrat et al., 2009 ). For UDCA-LPE used in this study, the same synthesis procedure was performed by ChemCon (Freiburg, Germany). Intracellular cAMP was determined by enzyme-linked immunosorbent assay kit (BT-730) from Hycultec GmbH (Beutelbach, Germany). Palmitate, bovine serum albumin (BSA), neonatal calf serum, and N-TER Nanoparticle small interfering RNA (siRNA) transfection system were obtained from Sigma-Aldrich (Taufkirchen, Germany). Brefeldin A and 8-(4-chlorophenylthio)-29-O-methyladenosine cAMP (8-CPT-29-O-Me-cAMP) were obtained from Biomol (Hamburg, Germany). cAMP, N6,O29-dibutyryl (dibutyryl-cAMP), 8-bromo-cAMP, KT5720 [(9R,10S,12S)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:39,29,19-kl] pyrrolo [3,4-i] [1, 6]benzodiazocine-10-carboxylic acid, hexyl ester], and protease inhibitor cocktails were obtained from Calbiochem (Darmstadt, Germany). The following were our sources of primary antibodies: SCD-1 (clone CD.E10) and fatty acid elongase (Elovl)6 (ab69857) were from Abcam (Cambridge, UK), cleaved poly(ADP-ribose) polymerase (PARP-1; clone E51) was from Epitomics (Hamburg, Germany), and Bim and cleaved caspase-3 (clone 5AIE) were from Cell Signaling Technologies (Frankfurt, Germany).
Hepatocyte Isolation. Hepatocytes were isolated from 7-to 10-week-old male C57BL/6 mice (Charles River Laboratories, Sulzfeld, Germany) by using a two-step collagenase perfusion technique and were purified by Percoll. Freshly isolated hepatocytes were plated and cultured for 4 hours in M199 medium containing Hanks' salts and L-glutamine (PAA, Cölbe, Germany) supplemented with 1% penicillin and streptomycin, 100 nM dexamethasone, 0.5 nM insulin, and 4% neonatal calf serum. Dead hepatocytes were removed, and the adhered cells were treated with freshly prepared Pal with or without UDCA-LPE in serum-free M199 medium on the same day of isolation.
Palmitate Preparation and Caspase-3 Assay. Pal stock solution in BSA was prepared according to a published procedure (Rahman et al., 2009) . Briefly, 250 ml of 200 mM Pal in ethanol was mixed with 4.5 ml of 27% BSA in phosphate-buffered saline (PBS). The total 5-ml volume was adjusted to pH 7.4 with 0.1 N NaOH until the mixture became clear. After treatment for the indicated time, hepatocytes were washed with PBS and lysed with 1% Triton X-100 in PBS. Cell lysates after centrifugation were subjected to determination of protein (Bio-Rad protein kit; Bio-Rad, Hercules, CA) and caspase-3/-7 activity using Caspase-3/-7
Glo kit (Promega, Mannheim, Germany). Luminescence was measured with a Fluostars Optima (BMG Labtech GmbH, Germany). For solvent controls, wells without Pal contained 0.5% BSA and 0.1% ethanol.
Immunoblotting. After treatment, mouse hepatocytes plated in six-well collagen coated plates were lysed and centrifuged at 13,000g, 4°C for 15 minutes. Cell lysates were separated by gel electrophoresis and transferred onto polyvinylidene fluoride membranes. Blots were treated with a primary antibody followed by a secondary antibody. Protein bands were visualized by using Luminata Forte ECL system (Millipore, Darmstadt, Germany) .
Lipid Extraction, Fatty Acid, and Phospholpid Analyses. Lipid extraction of 100-ml lysates of treated mouse hepatocytes was performed according to Folch's method by using 10 volumes 2:1 chloroform/methanol. After removal of protein precipitates, chloroform was collected and evaporated to complete dryness. Lipids were dissolved in 50 ml 3:2 hexane/isopropanol. TG levels normalized to milligrams of protein were determined with LabAssay Triglyceride kits (Wako GmbH, Neuss, Germany) using a microplate reader Mutiskan Ascent (ThermoFisher Scientific, Schwerte, Germany). Treated mouse hepatocytes were taken up into 200 ml of PBS and lysed by freeze-thawing. After centrifugation, lysates were Lipoprotection by UDCA-LPE at ASPET Journals on June 24, 2017 molpharm.aspetjournals.org subjected to fatty acid analyses by gas chromatography coupled to mass spectrometry (GC-MS) as previously described (Ecker et al., 2012) , and quantification of phospholipids by electrospray ionization tandem mass spectrometry (ESI-MS/MS) in positive mode was done using the setup described previously (Liebisch et al., 2004 ).
Analyses of UDCA-LPE and UDCA. Cell lysates were subjected to lipid extraction in the presence of D 4 -UDCA as an internal standard. UDCA-LPE and UDCA concentrations in samples and standards were determined using a liquid chromatography mass spectrometer (Waters 2695 interfaced with a Quattro Micro; Waters, Milford, MA) . For inhibition of caspase-3 activity, UDCA-LPE was more potent than chenodeoxycholate (CDCA) or taurine-conjugated UDCA (tauro-UDCA) when used at 60 mM. Data were mean 6 S.D., N = 6; ***P , 0.001 versus con;
Gene Expression by Reverse Transciption-Polymerase Chain Reaction. Total RNA of treated mouse hepatocytes was isolated using QIAGEN RNeasy Mini kit (Qiagen, Hilden, Germany). cDNA was synthesized from 2 mg of RNA using a Maxima First Strand cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany). The mRNA expression was analyzed in quadruplets by real-time polymerase chain reaction (PCR) using Applied Biosystems TaqMan gene expression assays with TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA) and run on an Applied Biosystem 7500 Fast real-time PCR machine by using Assay-On-Demand TaqMan primers. The expression level of targets in quadruplets was calculated using the D-C t transformation method and determined as a ratio of target gene normalized to housekeeping gene glyceraldehyde 3-phosphate dehydrogenase. PCR results were obtained from three or four independent experiments except for Fig. 5D , which shows representative results from two experiments.
siRNA and Transfection. SCD-1 siRNAs were designed and synthesized by Riboxx GmbH (Radebeul, Germany). Two siRNA pairs were used in our study: SCD-1 siRNA_1 (antisense: UUUA-CUUAAAGA CACCAGGCCCCC and sense: GGGGGCCUGGUGU CUUUAAGU AAA) and SCD-1 siRNA_2 (antisense: UAUUAGUA-CAUUCAUCUGGCCCCC and sense GGGGGCCAG AUGAAUGUA-CUAAUA). Negative control siRNAs were obtained from Eurogentec (Seraing, Belgium). After allowing mouse primary hepatocytes to adhere for 4 hours, cells were transfected with 50 nM control or SCD-1 siRNAs using N-TER Nanoparticle siRNA transfection reagent for 4 hours. Cells were subsequently treated with Pal with or without UDCA-LPE in serum-free M199 medium for an additional 9 or 20 hours.
Data Analysis. Results were expressed as mean 6 S.D. from at least two independent experiments performed at least in triplicates. For data in the figures, significance using analysis of variance with Bonferroni's test for multiple comparisons was determined by using GraphPad Prism 5 (GraphPad Software, San Diego, CA). For data in the tables, the significance for multiple comparisons was computed using a call of the SAS General Linear Model procedures (SAS Institute, Cary, NC) for Tukey's and Bonferroni's tests. Dunnett's test was used for multiple testing against the control group.
Results
UDCA-LPE Inhibits Lipoapoptosis in Part by cAMP/ Protein Kinase Signaling. Treatment of mouse hepatocytes with 300 mM Pal for 20 hours induced significant apoptosis as evident by increased expression of proapoptotic BCl-2 family Bim, cleaved caspase-3, and cleaved PARP-1 proteins (Fig. 1B) . Representative data from three experiments show that cotreatment of Pal with 60 mM UDCA-LPE significantly inhibited the expression of proapoptotic proteins ( Fig. 1B ) and caspase-3 activities (Fig. 1C) by .90%. IC 50 for UDCA-LPE lipoprotection was determined to be ∼32 mM (Fig.  1D ). The addition of UDCA-LPE 2 or 4 hours post Pal addition decreased the extent of lipoprotection, indicating that preincubatioin and coincubation were necessary for UDCA-LPE lipoprotection (Fig. 1E ). Apoptosis inhibition was not observed on cotreatment with 60 mM UDCA, oleate (18:1n-9), or palmitoleate (16:1n-7) (Fig. 1F ). Oleate or palmitoleate was found to be protective when used at 200 mM (data not shown), which was in accordance with previous reports (Listenberger et al., 2003; Collins et al., 2010) . Cotreatment with LPE or individually added UDCA 1 LPE partially inhibited apoptosis by only ∼25%. This finding is consistent with the reported antiapoptotic activity of LPE with a mechanism of MAPK activation (Nishina et al., 2006) . Pal cotreatment with other protective agents, i.e., chenodeoxycholic acid (Pellicciari et al., 2004) or tauro-UDCA (Miller et al., 2007) at 60 mM also did not elicit lipoprotection (Fig. 1G ), demonstrating the superiority of UDCA-LPE to some known cytoprotective lipids and bile acids.
Cytoprotective bile acids can activate cAMP that mediates apoptosis protection against toxic bile acids (Webster and Anwer, 1998) . It is hypothesized that UDCA-LPE as a bile acid-PL conjugate may mediate protection against Pal toxicity via cAMP (Kwon et al., 2004) . UDCA-LPE treatment of mouse hepatocytes for 30 minutes increased intracellular cAMP concentrations in a dose-dependent manner ( Fig. 2A) . Stimulation of cAMP by 100 mM UDCA was found to be lesser than that of UDCA-LPE. In a manner similar to that of UDCA-LPE, cotreatment of hepatocytes with dibutyryl-or 8-bromo-cAMP also inhibited Pal-induced apoptosis (Fig. 2B) . We further explored possible role of downstream cAMP effectors, namely, protein kinase A (PKA) and exchange protein activated by cAMP (EPAC) (Misra and Pizzo, 2005) . We found that the PKA inhibitor KT5720 partially blocked the protection by UDCA-LPE or dibutyryl cAMP (Fig. 2C ). Western blot analyses of cleaved caspase-3 and PARP-1 proteins also revealed that KT5720 partially reversed the inhibition of these proteins by UDCA-LPE ( Fig. 2D ), indicating an involvement of PKA in lipoprotection by UDCA-LPE. We excluded an involvement of EPAC because an EPAC activator CPT-2-Me-cAMP did not inhibit Pal-induced apoptosis and an EPAC inhibitor Brefeldin A did not reverse the ability of UDCA-LPE to inhibit lipoapoptosis (Fig. 2E) .
Effects of UDCA-LPE on Triglycerides and Fatty Acid Composition during Lipoprotection. Treatment of cultured cells with MUFA, such as oleate (18:1n-9) and palmitoleate (16:1n-7) used at 200 mM, is associated with accumulation of TGs (Listenberger et al., 2003; Li et al., 2009) and PLs (Collins et al., 2010) concomitant with protection against lipotoxicity. We therefore determined whether UDCA-LPE could protect lipoapoptosis by modulating TG and PL levels. Treatment of mouse hepatocytes with Pal for 20 hours elevated TG levels, which were further elevated by UDCA-LPE cotreatment (Fig. 3A) . Such further TG elevation was not observed on treatment with 60 mM UDCA, LPE, individually added UDCA 1 LPE, oleate, or palmitoleate (Fig.  3B) . Notably, treatment of hepatocytes with 75 mM UDCA-LPE could cause a moderate increase in TG levels (Fig. 3A) .
We next determined whether further elevation of TGs was associated with alterations of fatty acid composition during lipoprotection by UDCA-LPE. By using GC-MS, Pal treatment of mouse hepatocytes for 20 hours caused significant increases in saturated and 15-17 carbon fatty acids (Fig. 3C) . UDCA-LPE cotreatment showed a trend for inhibition of these increases concomitant with a trend for further increases of monounsaturated, more than two unsaturated as well as 18-19 and 22-24 carbon fatty acids. Detailed analysis shown in Table 1 revealed that UDCA-LPE cotreatment reduced the levels of Pal (16:0) by ∼27 nmol/mg protein (219.7 6 20 versus 192.7 6 8.1 for Pal and Pal 1 UDCA-LPE, respectively). Concomitantly, the levels of oleate (18:1n-9) were further increased by ∼21 nmol/mg protein (74.5 6 9.2 versus 95.7 6 4.4 for Pal and Pal 1 UDCA-LPE, respectively). We investigated further whether the UDCA-LPE molecule (which by itself contains oleate on the LPE moiety) could account for the observed increases in oleate. Intracellular concentrations of UDCA-LPE were ∼0.5 nmol/mg protein (Fig. 3D) , much lower , or 100 mM UDCA-LPE stimulated intracellular cAMP levels, whereas 100 mM UDCA had a weak effect. (B) Cotreatment with 100 mM dibutyryl or 800 mM 8-bromo-cAMP for 20 hours markedly inhibited Pal-induced caspase-3 activities in a manner similar to 60 mM UDCA-LPE. (C) Inhibition of lipoapoptosis by 60 mM UDCA-LPE or 100 mM dibutyryl cAMP was partially blocked by PKA inhibitor KT5720, which, at 5 mM, was pretreated 30 minutes before Pal addition. (D) UDCA-LPE inhibited Pal-induced upregulation of cleaved caspase-3 and cleaved PARP-1 proteins after 15 hours. This inhibition was partially blocked by 30-minute pretreatment with 10 mM KT5720. (E) An EPAC activator CPT-2-Me-cAMP used at 20 mM did not inhibit Pal-induced apoptosis after 20 hours. An EPAC inhibitor brefeldin A used at 100 mM with 1 hour of pretreatment did not reverse protective effects by UDCA-LPE. Data were mean 6 S.D., N = 6; *P , 0.05; ***P , 0.001 versus con; † P , 0.05 versus Pal; than those of the increased oleate. With UDCA-LPE treatment alone, intracellular concentrations of UDCA (Fig. 3D ) and total LPE (Table 2) were similar to those of controls of ∼0.3 and 1.55 nmol/mg protein, respectively, and the latter again could not account for the observed increased oleate. Thus, our data indicated an absence of UDCA-LPE hydrolysis to UDCA and LPE, which is consistent with our previous study using fluorescently labeled UDCA-LPE (Chamulitrat et al., 2009) . These data were consistent with the observed optimal lipoprotection by intact UDCA-LPE, but not by its metabolite UDCA or LPE (Fig. 1F) . Together with oleate (18: 1n-9), UDCA-LPE cotreatment showed a trend to increase even further the levels of homo-g-linoleate (20:3n-6), DPA (22: 5n-3), and DHA (22:6n-3) ( Table 1 ). The total fatty acid levels were increased on Pal treatment, and these levels were not altered by UDCA-LPE cotreatment (Fig. 3E) . Rather than by Role of SCD-1 in UDCA-LPE Lipoprotection. The mechanism for increases in TGs during lipoprotection has been demonstrated to involve conversion of SFA to MUFA by SCD-1 (Listenbeger et al., 2003; Collins et al., 2010) . In the liver (Li et al., 2009 ), MUFA provides metabolic adaptation for lipoprotection by incorporating SFA and MUFA into TGs and PLs. We therefore investigated a possible role of SCD-1 during UDCA-LPE lipoprotection. We observed time-dependent regulation of SCD-1 on the mRNA and protein levels (Fig. 4A) . Compared with Pal, UDCA-LPE cotreatment caused further increases in SCD-1 mRNA after 4 hours and SCD-1 protein after 9 hours, which may indicate an early response for MUFA synthesis to elicit protection during apoptosis observable at 20 hours. Treatment of mouse hepatocytes with Pal for 20 hours markedly decreased SCD-1 mRNA expression, which was not rescued by UDCA-LPE cotreatment, likely the result of inhibition of SCD-1 transcription by PUFAs (Ntambi, 1999) , which had an increased trend after Pal treatment (Table 1) . Cotreatment with LPE or individually added UDCA 1 LPE did not increase SCD-1 protein after 9 hours of treatment, indicating the importance of intact UDCA-LPE in SCD-1 induction (Fig. 4B) . Because the cAMP-PKA pathway could in part play a role in UDCA-LPE lipoprotection (Fig. 2) , PKA inhibitor KT5720 was used to test whether there was a cross-talk between cAMP and SCD-1 20:0) 3.63 6 0.4 1.3 6 0.07* 1.4 6 0.0* 2.9 6 1.0* ns Gondoic acid (20:1n-9) 1.6 6 0.2 1.2 6 0.1* 1.3 6 0.1 2.2 6 0.6* ns Homo-g-linoleic acid (20:3n-6) 4.9 6 0. The ability of UDCA-LPE to inhibit lipoapoptosis (two left panels) and to increase triglycerides (two right panels) was decreased on SCD-1 knockdown using SCD-1 siRNA-1 and SCD-1 siRNA-2. Data are mean 6 S.D., N = 4; *P , 0.05; ***P , 0.001 versus con; † P , 0.05 versus Pal or con siRNA. con, control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Lipoprotection by UDCA-LPE at ASPET Journals on June 24, 2017 molpharm.aspetjournals.org pathways. We found that KT5720 treatment did not significantly block UDCA-LPE-dependent upregulation of SCD-1 protein detectable at 9 hours or SCD-1 mRNA detectable at 4 hours (Fig. 4B ). This finding indicated that SCD-1 upregulation by UDCA-LPE cotreatment was unlikely to be mediated by cAMP and PKA. We performed SCD-1 knockdown by using siRNAs to determine a possible role of SCD-1 on UDCA-LPE lipoprotection (Fig. 4C) . In our hands, siRNA knocked down SCD-1 protein by only ∼50% after 9 hours of treatment. Pal and UDCA-LPE cotreatment significantly increased SCD-1 protein expression in control siRNA-transfected cells but failed to do so in SCD-1 siRNA-transfected cells. Compared with control siRNA-transfected cells, Pal treatment of SCD-1 knockdown cells caused markedly increased apoptosis, as seen by increased cleaved caspase-3 and cleaved PARP-1 protein expression (Fig. 4C) , which was consistent with previous reports (Li et al., 2009 ). In SCD-1-knockdown cells, the ability of UDCA-LPE to inhibit apoptosis became weaker, as quantitatively demonstrated by caspase-3 activity assay (Fig. 4D, left) . UDCA-LPE inhibited apoptosis by ∼60% in control siRNA-transfected cells and, to a lesser extent, by ∼40% in SCD-1 siRNA-1-or siRNA-2-transfected cells. Concomitantly, UDCA-LPE and Pal cotreatment significantly further increased TG levels in control siRNA-transfected cells (Fig.  4D, right) , and the ability of UDCA-LPE to further increased TG became less effective with SCD-1 knockdown. Thus, SCD-1 may in part contribute to UDCA-LPE lipoprotection for increases of TGs.
To explore the possible mechanisms for increases of more than two unsaturated (Fig. 3C) , as well as an increased trend of DPA (22:5n-3) and DHA (22:6n-3) (Table 1) , we measured mRNA expression of fatty acid desaturase (Fads) and Elovl (Moon et al., 2009; Green et al., 2010) genes. Similar to the earlier observation of SCD-1 upregulation at 4 hours, UDCA-LPE cotreatment further upregulated mRNA expression of Fads 1 (D6 desaturation) (Fig. 5A) , as well as Elovl5 and 6 (Fig. 5B) . Expression of Fads 2 (D5 desaturation) was not affected by Pal or UDCA-LPE treatment. Expression of de novo lipogenesis gene fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC1) was further increased by UDCA-LPE cotreatment after 20 hours of treatment (Fig. 5C ). Furthermore, expression of TG synthesis, lipolysis, b-oxidation, and metabolism transcription factor genes was measured in samples with 20 hours of treatment (Fig. 5D) . Pal treatment decreased the expression of diacylglycerol acyltransferase 1 (DGAT1) and liver X factor (LXR), which was rescued by UDCA-LPE cotreatment. UDCA-LPE cotreatment did not do so in the expression of DGAT2, adipocyte triglyceride lipase, acyl-CoA oxidase, peroxisome proliferator-activated receptor activator (PPAR)a, PPARg, and SREBP1c. Taken together, the addition of SCD-1 (D9 desaturation) UDCA-LPE protection against Pal was thus associated with the rescues of Fads1, Elovl5/6, DGAT1, and LXR by UDCA-LPE cotreatment, and this may account for increased polyunsaturated fatty acid (PUFA) contents ( Fig. 3C; Table 1 ).
UDCA-LPE Protects Lipoapoptosis by Modulating the Composition of Phospholipids. It has been shown that Pal (16:0) is significantly incorporated into PL (Collins et al., 2010) , and we further characterized the molecular species of PLs in our samples by using ESI-MS/MS. Pal treatment increased total phosphatidylcholine (PC) and phosphatidylethanolamine (PE) levels (Table 2) . UDCA-LPE cotreatment further increased the total PC (with a trend), and the total phosphatidylserine (PS) and LPE levels of ∼5, 1.6, and 0.4 nmol/mg protein, respectively. Pal treatment increased the levels of SFA and MUFA in PC, PE, and phosphatidylinositol (PI) ( Table 2) . UDCA-LPE cotreatment inhibited the increases in SFA while further increasing MUFA levels in PC, PE, and PI, supporting an SCD-1 mechanism for protection. Pal treatment increased PUFA levels in PC and PS, whereas UDCA-LPE cotreatment further increased PUFA in PS and with a trend in PC. LPE containing all SFA, MUFA, and PUFA classes was increased during lipoprotection by UDCA-LPE, likely by an SCD-1-independent mechanism, which may additionally contribute to apoptosis inhibition, shown to be mediated by MAPK (Nishina et al., 2006) .
Further detailed analyses of PL molecular species shown in Table 3 revealed that UDCA-LPE lipoprotection was associated with decreased levels of PC and PE species containing 14:0, 16:0, and 18:0, concomitant with increased levels of PC, PE, PS, PI, and LPE containing SFAs and MUFAs or PUFAs. MUFAs were mainly 18:1n-9, and PUFAs were mainly arachidonic acid (AA) (20:4n-6), eicosapentaenoate (20:5n-3), DPA (22:5n-3), and DHA (22:6n-3). During protection, the predominant species most affected by UDCA-LPE were PC 34:1 (PC 16:0,18:1) and PC 34:2 (PC 16:0,18:2), indicating an efficient incorporation of 16:0 into PC. During lipoprotection by UDCA-LPE, decreases of 16:0 and 18:0 fatty acids were also observed in ceramides and plasmalogen-based PE (Supplemental Table 1 ). During protection by UDCA-LPE, long-chain fatty acids (i.e., 22:0, 20:4, 20:5, 22:5, and 22:6) were also increased in ceramides, sphingomyelin, plasmalogenbased PE, and cholesterol.
Effects of UDCA-LPE on PL Composition and Comparison with UDCA, LPE, and cAMP. Our GC-MS data in Table 1 revealed that UDCA-LPE treatment alone could increase the levels of oleate (18:1n-9) (68.8 6 5.9 versus 89.2 6 12.1 nmol/mg protein for control and UDCA-LPE, respectively).
This result prompted us to analyze in greater detail the effects of UDCA-LPE alone on cellular fatty acid composition. Without Pal, UDCA-LPE treatment had a tendency to decrease Pal (16:0) levels (Table 1) but caused significant decreases in SFA in PC (1.87 6 0.1 versus 1.04 6 0.13 nmol/mg protein for control and UDCA-LPE, respectively) ( Table 2) . UDCA-LPE treatment alone caused an increase in PUFAs observed only in PS (6.69 6 0.23 versus 8.57 6 0.99 nmol/mg protein for control and UDCA-LPE, respectively) ( Table 2 ). This was the major contributor to the observed increased PUFA in PS when comparing the Pal and Pal 1 UDCA-LPE groups. The increases in PS by UDCA-LPE treatment alone corresponded to increases in PS 38:6, PS 40:6, and PS 42:6, most likely with combinations of 16:0, 18:0, or 18:1 with 22:5 or 22:6 as the major species affected by UDCA-LPE (Table 3) .
Although UDCA-LPE treatment alone caused significant increases in oleate (18:1n-9) detectable by GC-MS (Table 1) , these increases were not observed in any of the PLs analyzed by ESI-MS/MS (Tables 2 and 3 ). The increases in oleate by UDCA-LPE treatment alone may correspond to previously observed increases in TGs shown in Fig. 3A . Oleate generated by UDCA-LPE treatment may thus be readily incorporated into TG rather than into PL pools.
Because LPE (Fig. 1F) and cAMP (Fig. 2B) were able to inhibit lipoapoptosis, we further compared alterations of fatty acid composition among UDCA-LPE, UDCA, LPE, or cAMP by using GC-MS. Reported as the percent of mol fatty acids, we found that treatment with UDCA-LPE or LPE for 20 hours decreased cellular SFA while increasing MUFA levels (Fig.  6A) , consistent with the observed effects of UDCA-LPE shown in Table 1 . Treatment with UDCA-LPE or LPE was able to increase oleate (18:1n-9) levels (Fig. 6B, left) , suggesting a similar effect of LPE in stimulating MUFA synthesis, which (Fig. 1F) . However, UDCA-LPE was the only agent that increased the levels of more than two unsaturated fatty acids as seen by the increases in AA (20:4n-6) and DHA (22:6n-3) (Fig. 6B,  right) . These increases corresponded well with the observed upregulation of Fads1, Elovl6 and 5 mRNA by UDCA-LPE treatment alone (Fig. 5, A and B) . Treatment with UDCA did not cause any alterations in fatty acid composition, whereas that of 8-bromo-cAMP decreased oleate, AA, and DHA levels. The action of cAMP as a mediator of lipoprotection (Fig. 2) was unlikely related to the observed alteration of lipid metabolism ( Fig. 3C; Tables 1-3 ) and SCD-1 (Fig. 4) . Taken together, these results show that UDCA-LPE may exhibit maximal protection against Pal-induced apoptosis by two independent mechanisms, namely, cAMP/PKA signaling and alterations of fatty acid composition as outlined in Fig. 6C .
Discussion
It is accepted that not only the quantity of dietary fat but also the type of fat contributes to the onset and progression from steatosis to NASH. The liver plays a central role in wholebody lipid metabolism and responds rapidly to changes in dietary fat composition. Strategies for the development of therapeutic agents should involve lowering hepatic toxic SFA and at the same time inhibiting key deleterious events occurring in NASH. We here demonstrated that UDCA-LPE inhibited Pal-induced apoptosis in mouse hepatocytes while altering the composition of fatty acids such that total contents of TGs and PLs were accumulated. Lipidomic data revealed that this protection was accompanied with increases of mainly oleate (18:1n-9), DPA (22:5n-3), and 22: 6n-3 (DHA). Our study delineated molecular therapeutic pathways in UDCA-LPE's ability to inhibit lipoapoptosis by modulating composition of fatty acids in part via the SCD-1 (Fig. 6C) . UDCA-LPE was active as an intact compound in inhibiting Pal-induced apoptosis, which is in line with our previous studies (Chamulitrat et al., 2009 ). This exemplifies the significance of UDCA and LPE conjugation rendering its superiority over unconjugated bile acid (Pellicciari et al., 2004 ) and a preference of PL for conjugation (Miller et al., 2007) . Conjugated bile acids have been shown to activate receptor tyrosine kinases and intracellular signaling Fig. 6 . Effects of UDCA-LPE, its metabolites, and cAMP on fatty acid composition of mouse hepatocytes. (A) Based on the percent of mol fatty acids, treatment of mouse hepatocytes with 60 mM UDCA-LPE or LPE for 20 hours caused marked decreases in saturated fatty acids concomitant with increases of monosaturated or unsaturated fatty acids. The opposite was found for 800 mM 8-bromo-cAMP treatment. (B) UDCA-LPE or LPE treatment of 20 hours increased oleate levels. UDCA-LPE was the only compound that increased the levels of AA and DHA, whereas 8-bromo-cAMP decreased these levels. (C) Proposed mechanisms for UDCA-LPE protection against Pal-induced apoptosis in mouse hepatocytes include a minor pathway involving cAMP/PKA signaling, and alterations of fatty acid composition as a major pathway. UDCA-LPE cotreatment with Pal caused a shift of fatty acid metabolism from SFA to MUFA and PUFA. These were concomitant with increased TGs and PLs. The latter were observed in various PC, PE, PS, PI, and LPE species. Data were mean 6 S.D. in A and B, N = 3; *P , 0.05 versus con. con, control.
Lipoprotection by UDCA-LPE at ASPET Journals on June 24, 2017 molpharm.aspetjournals.org pathways in a G protein-coupled receptor (GPCR)-dependent manner (Hutchinson et al., 2008) . GPCR activation leads to an elevation of cAMP (Hutchinson et al., 2008) , which mediates apoptosis inhibition (Webster and Anwer, 1998; Kwon et al., 2004) . The observed UDCA-LPE lipoprotection via cAMP/PKA signaling supports the possibility that UDCA-LPE may interact with specific GPCRs, among which are lipid-sensing GPCRs [e.g., sphingosine-1-phosphate receptor 2 (Studer et al., 2012) and adenosine A2a receptor (Imarisio et al., 2012) ]. UDCA-LPE (or cAMP generated by UDCA-LPE) may interact with these GPCRs to induce PKA signaling leading to activation of cytoprotective signals Akt and ERK (Dent et al., 2005) . UDCA-LPE indeed induces Akt and ERK activation (Chamulitrat et al., 2009) .
During lipoprotection (Fig. 6C) , GC-MS and ESI-MS/MS analyses showed that UDCA-LPE increased elongation from Pal (16:0) to stearate (18:0), which was converted to oleate (18: 1n-9) by SCD-1 (Listenberger et al., 2003; Collins et al., 2010) . As we observed, increases in Fads1 and Elovl5/6 during lipoprotection by UDCA-LPE, elongation, and desaturation of linoleate (18:2n-6) and linolenate (18:3n-3) generate AA (20:4n-6), 22:5n-3, and 22:6n-3 as end products of PUFA syntheses (Moon et al., 2009; Green et al., 2010) . Furthermore, the increases in these v-3 PUFAs were uniquely specific for UDCA-LPE, particularly in the PS pool. UDCA-LPE lipoprotection was associated with a reduction of toxic SFA concomitant with increases in MUFAs in PC and PE as well as increases of PUFA in PC and PS. We also observed further elevation of TG levels during UDCA-LPE lipoprotection. We did not perform detailed fatty acid analysis of TG pools; however, TG containing very long-chain fatty acids were previously shown to be associated with protection (Hall et al., 2010) . Further elevation of TGs by UDCA-LPE cotreatment was found to be on the order of ∼1 mmol/mg protein (Fig. 3,  A and B) , which correlates with the rescues of reduced expression of DGAT1 and metabolic nuclear receptor LXR (Fig. 5D ). Further studies are needed to determine whether UDCA-LPE is an LXR agonist that may mediate the protective actions of v-3 PUFA (Jung et al., 2011) . Incorporation of fatty acids into TGs can be a major contributor in diverting SFAs away from apoptosis pathways. This is supported by previous data showing that inhibition of TG accumulation in obese mice worsens liver damage (Yamaguchi et al., 2007) . Among PL types, PC and LPE were mostly affected during lipoprotection by UDCA-LPE. The metabolically generated LPE may additionally contribute to lipoprotection of UDCA-LPE (Nishina et al., 2006) . The observed increases in the predominant PC 34:1 (most likely 16:0, 18:1) species showed that Pal and oleate were readily incorporated into PC, again diverting Pal away from apoptosis. Our current data are consistent with the notion that PC species are indeed protective against steatosis (Niebergall et al., 2011) . PC species containing MUFAs are present in higher concentrations in cells overexpressed with antiapoptosis Bcl-2 (Cantrel et al., 2009) . Furthermore, heat stress has been shown to increase contents of saturated fatty acids while decreasing those of PUFAs, particularly AA (20:4n-6) (Balogh et al., 2010) . Associated with protection, increases in PUFAs, such as, AA, DPA, and DHA, were observed not only in PL but also in PE-based plasmalogen pools (Wallner and Schmitz, 2011) . These PUFA-containing lipids may alter membrane lipid remodeling and protect cells by increasing membrane fluidity (Stubbs and Smith, 1984) .
AA (20:4n-6), DPA (22:5n-3), and DHA (22:6n-3) were identified as the main PUFAs, which were increased by UDCA-LPE treatment alone in a similar way to those fatty acids found during UDCA-LPE lipoprotection (Table 3) . These increases in PUFAs may be due to the ability of UDCA-LPE to upregulate Fads1, Elovl6, FAS, and PPARg mRNA expression (Fig. 5) . These increases were uniquely specific for UDCA-LPE as its metabolite UDCA, LPE, or cAMP with lesser effectiveness in apoptosis inhibition did not increase these PUFA. UDCA-LPE alone increased DPA (22:5n-3) and DHA (22:6n-3) contents in PS, thus supporting the importance of these species to play a role in cytoprotection (Kim et al., 2010) . DHA is a precursor of potent anti-inflammatory signaling molecules (Moon et al., 2009; Kim et al., 2010) . As v-6 and v-3 PUFA are key components of membrane PL, their levels are known to be decreased in livers of NASH patients (Puri et al., 2007) . The administration of DHA (22:6n-3) in NASH mice (Depner et al., 2013) and in children with fatty liver (Nobili et al., 2011) has been shown to be beneficial for treatment of this liver disease. The ability of UDCA-LPE to increase DHA bolsters its therapeutic use by strengthening PL membranes, increasing cell membrane fluidity, and replenishing the depleted DHA in NASH livers. Under in vivo conditions, TGs and PLs may be hydrolyzed by lipases and phospholipases to release free v-3 PUFA, which can be subjected to b-oxidation (Hall et al., 2010) . AA (20:4n-6) and DHA (22:6n-3) have been shown to suppress nuclear SREBP1c (Ntambi, 1999; Jump et al., 2008; Moon et al., 2009 ), which in turn leads to decreased transcription of de novo lipogenesis genes in vivo. Consistently, we found that de novo lipogenesis gene expression in the livers of mice fed with a high-fat diet was markedly inhibited by chronic treatment with UDCA-LPE .
In conclusion, UDCA-LPE protected lipoapoptosis by inducing a shift in fatty acid content toward MUFAs and PUFAs for incorporation into TGs and PLs concomitant with decreased Pal and SFA and rendering them unavailable for apoptosis. UDCA-LPE protected apoptosis by uniquely increasing PUFAs in PC and PS for cell membrane remodeling and stabilization. Our in vitro results provide mechanistic insights of a drug candidate UDCA-LPE for treatment of NASH by its unique metabolic reprogramming that minimizes damage brought on by excessive SFA.
